Product Profile
LUMALAR-CQ Tablets
LUMALAR-CQ contains artemether 20mg and lumefantrine 120mg as its active pharmacological ingredients. For the Nigerian market, LUMALAR-CQ is registered, advertised, promoted, and distributed in the following pack sizes: 1x6, 1x12, 1x18, 1x24, 30x6, 30x12, 30x18, and 30x24. These packs are indicated by the weight of prospective patients that coincide with age groups accordingly and respectively. For instance, the x6, x12, x18, and x24 packs are indicated for the 5kg-15kg, 15kg-25kg, 25kg-35kg, and the 35kg and above weights that also indicate for infants, children and adults respectively.
Pharmaceutical Form
LUMALAR-CQ is a yellow circular tablet, which is scored on one side and plane on the other side.
Mechanism of Action
The site of anti-Malarial action of both components is the food vacuole of the Malaria parasite, where they are thought to interfere with the conversion of haem, a toxic intermediate, which is produced during hemoglobin breakdown, to the non-toxic hemozoin.
Therapeutic Indication
LUMALAR-CQ is indicated for the treatment of uncomplicated cases of Malaria due to Plasmodium falciparum in adults, children, and infants of 5kg and above.
Method of Administration
This medication is administered through the oral route. Your physician or pharmacist will guide you on the right dosing schedule.
Contra-indication
Hypersensitivity to artemether, lumefantrine or to any of the excipient. For more information, please see your physician or pharmacist for professional opinion and advice.